BALCAO · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Sangamo Therapeutics, Inc. SGMOQ
17 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 39.6M
Revenue, FY2025 · full 17-year series below
Revenue $M
Net income $M
FY2025 · Revenue 39.6 · Net income -122.9
Compound annual growth
Revenue compounded at −19.7% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−311 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -306.5% · Net -310.8%
ROE
FY2025 · ROE -2891.8%
Each USD of equity lost 2892 cents this year.
The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.1 | −0.1 | −0.3 | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.1 | −0.1 | −0.3 | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Income tax $B | −0.0 | −0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | −0.0 | 0.0 | · | · | · | · | · |
| Net income $B | −0.1 | −0.1 | −0.3 | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.1 | −0.1 | −0.2 | −0.2 | −0.3 | 0.2 | −0.2 | −0.0 | 0.0 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −0.44 | −0.49 | −1.48 | −1.25 | −1.23 | −0.90 | −0.85 | −0.70 | −0.70 | −1.02 | −0.58 | −0.39 | −0.48 | −0.42 | −0.71 | −0.55 | −0.44 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −2891.8 | −185.4 | −136.5 | −57.4 | −40.8 | −26.0 | −23.8 | −24.7 | −33.7 | −43.6 | −20.4 | −16.1 | −28.5 | −30.7 | −52.6 | −38.9 | −25.9 |
| Shares out B | 0.35 | 0.21 | 0.18 | 0.17 | 0.15 | 0.14 | 0.12 | 0.10 | 0.09 | 0.07 | 0.07 | 0.07 | 0.06 | 0.05 | 0.05 | 0.05 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 65 reconciliationsAUDITED
Reconciled in 17 of 19 fiscal years. 11 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onOTC market
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2009